c-Met (N-terminal) Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

c-Met (N-terminal) Polyklonal Antikörper für WB, IHC, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen(3)

Kat-Nr. : 19971-1-AP

Synonyme

---

• 

  WB analysis of HeLa using 19971-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 19971-1-AP (c-Met (N-terminal) antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human breast cancer using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human breast cancer using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human colon using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human colon using 19971-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon tissue slide using 19971-1-AP (c-Met (N-terminal) antibody at dilution of 1:50 (under 40x lens).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen
• Erfolgreiche Detektion in IHC: humanes Mammakarzinomgewebe, humanes Kolongewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:1000
• Immunhistochemie (IHC): IHC : 1:50-1:200

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 2 publications below
• IHC: See 1 publications below

Produktinformation

19971-1-AP bindet in WB, IHC, ELISA c-Met (N-terminal) und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• In Publikationen genannte Reaktivität: human, Maus
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: Peptid
• Vollständiger Name: met proto-oncogene (hepatocyte growth factor receptor)
• Berechnetes Molekulargewicht: 156 kDa
• Beobachtetes Molekulargewicht: 140 kDa, 50 kDa
• GenBank-Zugangsnummer: NM_000245
• Gene symbol: MET
• Gene ID (NCBI): 4233
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). This antibody recognizes the N-term of c-Met.

Publikationen

Species	Application	Title
human	WB	Oncogene; A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.; Authors - F Yan
human	WB	Carcinogenesis; MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1.; Authors - Wu Jianmin J
mouse	IHC	Am J Pathol; PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.; Authors - Wen-Cheng Chung